Table 3. Univariate and multivatiate analysis of overall survival.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age (>50)	0.63 [0.24–1.62]	0.335	0.90 [0.148–5.5]	0.91
ER (positive)	1.15 [0.44–3.01]	0.77	0.50 [0.052–4.8]	0.549
PR (positive)	4.79 [1.29–17.9]	0.0196	26.73 [0.369–1,937.8]	0.133
HER2 (positive)	0.35 [0.12–1.01]	0.0512	0.66 [0.030–14.7]	0.794
TNBC (yes)	2.13 [0.67–6.82]	0.202	5.43 [0.4274–69.4]	0.193
Grade (III)	1.54 [0.57–4.18]	0.399	1.82 [0.433–7.7]	0.414
Number (>3)	0.89 [0.32–2.54]	0.834	0.62 [0.071–5.4]	0.668
Ki-67 (>35%)	0.89 [0.35–2.26]	0.805	0.50 [0.094–2.7]	0.418
Lung metastasis (yes)	0.85 [0.33–2.16]	0.729	3.53 [0.526–23.8]	0.194
Liver metastasis (yes)	2.72 [0.97–7.66]	0.0583	5.48 [0.802–37.5]	0.083
Bone metastasis (yes)	2.93 [0.99–8.58]	0.0505	1.04 [0.170–6.4]	0.962
Other metastasis (yes)	2.07 [0.76–5.66]	0.157	5.41 [0.887–32.9]	0.067

Note:

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; TNBC, triple-negative breast cancer.